Track topics on Twitter Track topics that are important to you
On 4 December, the US Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to ImmunityBio’s N-803, an interleukin-15...Read More... The post FDA grants breakthrough ther...
Immunotherapy company ImmunityBio has partnered with Microsoft to leverage the latter’s Azure platform to create a 3D model of Covid-19’s...Read More... The post ImmunityBio and Microsoft create 3...
The FDA granted ImmunityBio's investigational candidate N-803 Breakthrough Therapy designation to be combined with Bacillus C -More-
Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superago...
First demonstration of durable control of viremia without antiviral therapy in 9 of 13 SHIV-infected monkeys receiving combination therapy with N-803 and broadly neutralizing antibodies; Study result...
Results of Phase 1 and 2 studies in BCG Unresponsive Non-Muscle Invasive Bladder Cancer in High Risk Carcinoma in Situ Disease Earn FDA Breakthrough Status for ImmunityBio’s IL-15 Superagonist Comp...
Joint efforts combine a total of 24 petaflops of GPU computing power between ImmunityBio and Microsoft, enabling simulation of 200 μs per day of binding between the COVID-19 spike protein and the ho...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demon...
ImmunityBio, is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protei...
ImmunityBio, Inc. is a privately held immunotherapy company with a broad portfolio of biological molecules at clinical stages of development. The Companyâs goals are to employ this portfolio to ...
We have published hundreds of ImmunityBio, Inc. news stories on BioPortfolio along with dozens of ImmunityBio, Inc. Clinical Trials and PubMed Articles about ImmunityBio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunityBio, Inc. Companies in our database. You can also find out about relevant ImmunityBio, Inc. Drugs and Medications on this site too.
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...